Комбинированная терапия акарбозой с метформином: успешный контроль гликемии и предупреждение истощения инсулярного аппарата
Комбинированная терапия акарбозой с метформином: успешный контроль гликемии и предупреждение истощения инсулярного аппарата
Комбинированная терапия акарбозой с метформином: успешный контроль гликемии и предупреждение истощения инсулярного аппарата. Consilium Medicum. 2009; 11 (12): 25–28.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Chiasson JL, Gomis R, Hanefeld M et al. The Stop-NIDDM Trial. Diabetes Care 1998; 10 (21): 1720–5.
2. National Diabetes Data Group Classification and diagnosis of diabetes Mellitus and other categories of glucose Intolerance. Diabetes 1979; 28: 1039–57.
3. The Expert Committee on the Diagnosis Report of the Expert Committee on the and Classification of Diabetes Mellitus. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97.
4. Little RR, England JD, Wiedmeyer HM. Relationship of glycosylated hemoglobin et al. to oral glucose tolerance: implications for diabetes screening. Diabetes 1988; 37: 60–4.
5. Fuller JH, Shipley MJ, Rose G et al. Coronary-heart disease risk and impiared glucose tolerance: the Whitehall Study, Lancet 1980; 1373–6.
6. Gerich JE. Metabolic abnormalities in impiared glucose tolerance. Metabolism Сlin and Exp 1997; 46 (12): 40–3.
7. Harris M. Impiared glucose tolerance-Prevalence and conversion to NIDDM. Diabet Med 1996; 13: S9–S11.
8. Gray AM. Оценка показателя стоимость-эффект при лечении больных сахарным диабетом 2 типа. Медикография. 1999; 21 (4): 15–9.
9. ADA, American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21: 296–309.
10. DeFronzo RA. Med Clin N Am 2004; 88: 787–835.
11. Hollander PA, Elbein SC. Role of orlistat in the treatment of obese Hirsch IB, et al. patients with type 2 diabetes. Diabetes Care 1988; 1288–94.
12. Keina..nen-Kiukaanniemi S. Tuomilehto Type 2 diabetes can be prevented by J, Lindstro..m J et al. lifestyle intervention: the results from Finnish Diabetes Prevention Study. «Diabetes in the new millenium», 4th International coference St Vincent Declaration Primary Care Diabetes Group, Prague, 2000; Oct. 13–14: p. 21.
13. Chiasson JL et al. The stop-NIDDM trial. An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care 1998; 21: 1720–5.
14. Yang Wenying, Lin Lixiang. The preventive effect of Acarbose and Qi Jinwu et al. Metfor min on the IGT population from becoming dia betes mellitus: a 3-year multicentral prospective study. Clin J Endocrinol 2001; 3: 1–7.
2. National Diabetes Data Group Classification and diagnosis of diabetes Mellitus and other categories of glucose Intolerance. Diabetes 1979; 28: 1039–57.
3. The Expert Committee on the Diagnosis Report of the Expert Committee on the and Classification of Diabetes Mellitus. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97.
4. Little RR, England JD, Wiedmeyer HM. Relationship of glycosylated hemoglobin et al. to oral glucose tolerance: implications for diabetes screening. Diabetes 1988; 37: 60–4.
5. Fuller JH, Shipley MJ, Rose G et al. Coronary-heart disease risk and impiared glucose tolerance: the Whitehall Study, Lancet 1980; 1373–6.
6. Gerich JE. Metabolic abnormalities in impiared glucose tolerance. Metabolism Сlin and Exp 1997; 46 (12): 40–3.
7. Harris M. Impiared glucose tolerance-Prevalence and conversion to NIDDM. Diabet Med 1996; 13: S9–S11.
8. Gray AM. Оценка показателя стоимость-эффект при лечении больных сахарным диабетом 2 типа. Медикография. 1999; 21 (4): 15–9.
9. ADA, American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21: 296–309.
10. DeFronzo RA. Med Clin N Am 2004; 88: 787–835.
11. Hollander PA, Elbein SC. Role of orlistat in the treatment of obese Hirsch IB, et al. patients with type 2 diabetes. Diabetes Care 1988; 1288–94.
12. Keina..nen-Kiukaanniemi S. Tuomilehto Type 2 diabetes can be prevented by J, Lindstro..m J et al. lifestyle intervention: the results from Finnish Diabetes Prevention Study. «Diabetes in the new millenium», 4th International coference St Vincent Declaration Primary Care Diabetes Group, Prague, 2000; Oct. 13–14: p. 21.
13. Chiasson JL et al. The stop-NIDDM trial. An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care 1998; 21: 1720–5.
14. Yang Wenying, Lin Lixiang. The preventive effect of Acarbose and Qi Jinwu et al. Metfor min on the IGT population from becoming dia betes mellitus: a 3-year multicentral prospective study. Clin J Endocrinol 2001; 3: 1–7.
Авторы
А.М.Мкртумян
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.